{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:52:30Z","timestamp":1793109150999,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC0901502"],"award-info":[{"award-number":["2016YFC0901502"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2011CB944004"],"award-info":[{"award-number":["2011CB944004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174115"],"award-info":[{"award-number":["82174115"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jare.2025.03.023","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T18:29:54Z","timestamp":1742495394000},"page":"549-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pathogenicity of novel GLA gene missense mutations in Fabry disease and the therapeutic impact of migalastat"],"prefix":"10.1016","volume":"79","author":[{"given":"Wenkai","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jare.2025.03.023_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12052063","article-title":"Biochemical mechanisms beyond glycosphingolipid accumulation in fabry disease: might they provide additional therapeutic treatments?","volume":"12","author":"Bertoldi","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jare.2025.03.023_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107603","article-title":"Global reach of over 20 years of experience in the patient-centered Fabry Registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community","volume":"139","author":"Wanner","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13023-022-02215-x","article-title":"Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective","volume":"17","author":"Ezgu","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jare.2025.03.023_b0025","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"9647","key":"10.1016\/j.jare.2025.03.023_b0030","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jare.2025.03.023_b0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"issue":"14","key":"10.1016\/j.jare.2025.03.023_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147663","article-title":"Chromosome inactivation in carriers of Fabry disease: review and meta-analysis","volume":"22","author":"Viggiano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2025.03.023_b0050","article-title":"Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene","volume":"20","author":"Hossain","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"10.1016\/j.jare.2025.03.023_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017098","article-title":"Fabry disease due to D313Y and novel GLA mutations","volume":"7","author":"Koulousios","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jare.2025.03.023_b0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/jhg.2011.31","article-title":"Fabry-database.org: database of the clinical phenotypes, genotypes and mutant \u03b1-galactosidase A structures in Fabry disease","volume":"56","author":"Saito","year":"2011","journal-title":"J Hum Genet"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12882-023-03138-w","article-title":"The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages","volume":"24","author":"Guo","year":"2023","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1016\/j.jare.2025.03.023_b0070","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s10038-019-0599-z","article-title":"Mutation spectrum of \u03b1-Galactosidase gene in Japanese patients with Fabry disease","volume":"64","author":"Kobayashi","year":"2019","journal-title":"J Hum Genet"},{"issue":"3","key":"10.1016\/j.jare.2025.03.023_b0075","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000503998","article-title":"Functional characterization and pharmacological evaluation of a novel GLA missense mutation found in a severely affected Fabry disease family","volume":"144","author":"Varela","year":"2020","journal-title":"Nephron"},{"issue":"21","key":"10.1016\/j.jare.2025.03.023_b0080","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jare.2025.03.023_b0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"Faseb j"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"Shin","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.jare.2025.03.023_b0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group","volume":"34","author":"Gal","year":"2011","journal-title":"J Inherit Metab Dis"},{"issue":"4154","key":"10.1016\/j.jare.2025.03.023_b0125","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.185.4154.862","article-title":"Amino acid difference formula to help explain protein evolution","volume":"185","author":"Grantham","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.jare.2025.03.023_b0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12882-015-0015-7","article-title":"A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease","volume":"16","author":"Ali","year":"2015","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0135","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/humu.9520","article-title":"Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone","volume":"29","author":"Shimotori","year":"2008","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpdd.1","article-title":"Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers","volume":"2","author":"Johnson","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.jare.2025.03.023_b0145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.jare.2025.03.023_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161330","article-title":"Genotype: a crucial but not unique factor affecting the clinical phenotypes in Fabry disease","volume":"11","author":"Pan","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jare.2025.03.023_b0155","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/humu.9327","article-title":"Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease","volume":"25","author":"Sch\u00e4fer","year":"2005","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jare.2025.03.023_b0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.jare.2025.03.023_b0170","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s42358-019-0111-7","article-title":"Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients","volume":"60","author":"Rosa Neto","year":"2020","journal-title":"Adv Rheumatol"},{"issue":"4","key":"10.1016\/j.jare.2025.03.023_b0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/jhg.2015.155","article-title":"Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China","volume":"61","author":"Chen","year":"2016","journal-title":"J Hum Genet"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"issue":"12","key":"10.1016\/j.jare.2025.03.023_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084267","article-title":"Comparative study of structural changes caused by different substitutions at the same residue on \u03b1-galactosidase A","volume":"8","author":"Saito","year":"2013","journal-title":"PLoS One"},{"issue":"455","key":"10.1016\/j.jare.2025.03.023_b0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2007.00198.x","article-title":"Structure-function relationships in alpha-galactosidase A","volume":"96","author":"Garman","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jare.2025.03.023_b0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.cb.05.110189.001425","article-title":"Protein oligomerization in the endoplasmic reticulum","volume":"5","author":"Hurtley","year":"1989","journal-title":"Annu Rev Cell Biol"},{"issue":"4","key":"10.1016\/j.jare.2025.03.023_b0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0092-8674(90)90104-M","article-title":"Protein degradation in the endoplasmic reticulum","volume":"62","author":"Klausner","year":"1990","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.jare.2025.03.023_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315261","article-title":"Abnormal Pre-mRNA splicing in exonic fabry disease-causing GLA mutations","volume":"23","author":"Alfen","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jare.2025.03.023_b0215","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/gutjnl-2013-305981","article-title":"Exonic variants affecting pre-mRNA splicing add to genetic burden in chronic pancreatitis","volume":"63","author":"Beer","year":"2014","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.jare.2025.03.023_b0220","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1136\/gutjnl-2017-313948","article-title":"In vitro and in silico evidence against a significant effect of the SPINK1 c.194G>A variant on pre-mRNA splicing","volume":"66","author":"Wu","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jare.2025.03.023_b0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/ddg055","article-title":"Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor","volume":"12","author":"Duan","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.jare.2025.03.023_b0230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem J"},{"issue":"6968","key":"10.1016\/j.jare.2025.03.023_b0235","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nature02262","article-title":"Quality control in the endoplasmic reticulum protein factory","volume":"426","author":"Sitia","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2025.03.023_b0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.braindev.2020.06.015","article-title":"Chaperone therapy for molecular pathology in lysosomal diseases","volume":"43","author":"Suzuki","year":"2021","journal-title":"Brain Dev"},{"issue":"9","key":"10.1016\/j.jare.2025.03.023_b0245","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s10038-008-0316-9","article-title":"Structural characterization of mutant alpha-galactosidases causing Fabry disease","volume":"53","author":"Sugawara","year":"2008","journal-title":"J Hum Genet"},{"issue":"4","key":"10.1016\/j.jare.2025.03.023_b0250","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"issue":"Suppl 1","key":"10.1016\/j.jare.2025.03.023_b0255","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jare.2025.03.023_b0260","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.12.017","article-title":"Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease","volume":"96","author":"Sugawara","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.jare.2025.03.023_b0265","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.jare.2025.03.023_b0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Feldt-Rasmussen","year":"2020","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.jare.2025.03.023_b0275","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.jare.2025.03.023_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030956","article-title":"Assessment of gene variant amenability for pharmacological chaperone therapy with 1-deoxygalactonojirimycin in Fabry disease","volume":"21","author":"Lukas","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2025.03.023_b0285","article-title":"\u03b1-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response","volume":"33","author":"Consolato","year":"2022","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"10.1016\/j.jare.2025.03.023_b0290","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.molmed.2012.06.010","article-title":"ER stress-induced inflammation: does it aid or impede disease progression?","volume":"18","author":"Garg","year":"2012","journal-title":"Trends Mol Med"},{"issue":"19","key":"10.1016\/j.jare.2025.03.023_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197397","article-title":"Misfolding of Lysosomal \u03b1-galactosidase a in a fly model and its alleviation by the pharmacological chaperone migalastat","volume":"21","author":"Braunstein","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6059","key":"10.1016\/j.jare.2025.03.023_b0300","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225001833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225001833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:59:20Z","timestamp":1778835560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225001833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"alternative-id":["S2090123225001833"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.03.023","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenicity of novel GLA gene missense mutations in Fabry disease and the therapeutic impact of migalastat","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}